Preferred Label : Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;
NCIt synonyms : Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Pertuzumab/Trastuzumab/Hyaluronidase-zzxf;
NCIt related terms : Pertuzumab and Trastuzumab hyaluronidase;
NCIt definition : A ready-to-use fixed-dose combination of pertuzumab and trastuzumab, both recombinant
humanized monoclonal antibodies directed against the tyrosine kinase receptor (TKR)
human epidermal growth factor receptor 2 (HER2; HER-2; receptor tyrosine-protein kinase
erbB-2), and hyaluronidase-zzxf, a biosimilar of the recombinant form of the naturally
occurring endoglycosidase hyaluronidase, with antineoplastic activity that can be
used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration,
hyaluronidase-zzxf temporarily breaks down the hyaluronan barrier, which decreases
viscosity of, and allows both pertuzumab and trastuzumab to spread rapidly through
the interstitial space. This improves access to lymphatic and capillary vessels and
facilitates the absorption of both antibodies into the bloodstream. Pertuzumab targets
and binds to the extracellular dimerization domain (subdomain II) of HER2 and blocks
ligand-dependent heterodimerization of HER2 with other HER family members, including
EGFR, HER3 and HER4. This inhibits ligand-initiated intracellular signaling and prevents
the activation of the mitogen-activated protein (MAP) kinase and the phosphoinositide
3-kinase (PI3K) signaling pathways, leading to growth arrest and apoptosis in HER2-overexpressing
tumor cells, respectively. Trastuzumab targets and binds to subdomain IV of HER2 and
inhibits ligand-independent, HER2 mediated cell proliferation and inhibits the PI3K
signaling pathway in HER2-overexpressing tumor cells. Both antibodies induce an antibody-dependent
cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed
in many adenocarcinomas, particularly breast adenocarcinomas.;
Drug name : Phesgo;
NCI Metathesaurus CUI : CL1636756;
Codes from synonyms : 111391;
Origin ID : C173339;
UMLS CUI : C5390937;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
